Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Promedior Initiates Phase 2 Clinical Study of PRM-151 in Myelofibrosis

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/09/2013 | 03:06pm CEST

Development Progress Builds on Encouraging Clinical Data in Idiopathic Pulmonary Fibrosis (IPF)

Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that it has initiated a Phase 2 clinical trial to evaluate PRM-151, its lead product candidate, in patients with myelofibrosis. Promedior is advancing PRM-151, a recombinant form of an endogenous human protein that offers the potential to prevent and potentially reverse fibrosis. The Phase 2 clinical study of PRM-151 in patients with myelofibrosis, which is expected to complete in 2014, expands Promedior's clinical focus beyond IPF to myelofibrosis, another serious, life-limiting orphan disease with significant unmet medical need.

"Advancing the clinical development of PRM-151, our lead product candidate, into clinical studies in myelofibrosis patients is a significant milestone for Promedior," said Elizabeth G. Trehu, MD, FACP, Promedior's Chief Medical Officer. "We are optimistic that data from this study, combined with the encouraging data in IPF, will demonstrate that PRM-151's novel mechanism of action is applicable to a wide range of fibrotic diseases."

Promedior's clinical development program in myelofibrosis with PRM-151 builds upon a randomized, placebo-controlled clinical study in patients with IPF, in which PRM-151 was generally safe and well?tolerated and resulted in a mean improvement in Forced Vital Capacity (FVC) at 8 weeks after dosing for only two weeks, whereas patients receiving placebo had a decline in FVC. In addition, PRM-151 has demonstrated broad anti-fibrotic activity in multiple industry standard preclinical models of fibrotic disease, including pulmonary fibrosis, acute and chronic nephropathy, liver fibrosis, and age-related macular degeneration.

"Despite the success of JAK inhibitors, there is still a critical need for new therapeutic approaches for patients with myelofibrosis. With its unique mechanism of action that offers the potential to prevent and reverse fibrosis, Promedior's PRM-151 has the potential to become a first-in-class disease-modifying treatment for this debilitating disease," said Srdan Verstovsek, MD, PhD, Professor and Section Chief for Myeloproliferative Neoplasms, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, and principal investigator for the study.

This clinical trial is a multi-center, two stage, adaptive design Phase 2 study to determine the efficacy and safety of PRM-151 as a single agent or added to a stable dose of ruxolitinib in patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), or Post-Essential Thrombocythemia MF (post-ET MF). The primary endpoint is response rate according to the International Working Group- Myeloproliferative Neoplasms Research and Treatment criteria, a comprehensive assessment tool designed by an international group of experts to objectively measure the effectiveness of treatments for MF¹. Approximately 24 patients are expected to enroll in the first stage of the study, with up to 80 additional patients in the second stage. For additional details about this clinical trial, please visit www.clinicaltrials.gov.

About Myelofibrosis

Myelofibrosis (MF), a type of myeloproliferative neoplasm, is a serious, life-limiting cancer that is characterized by fibrosis of the bone marrow. Replacement of the bone marrow by scar tissue prevents the normal production of blood cells, leading to anemia, fatigue, and increased risk of bleeding and infection. Production of blood cells shifts to the spleen and liver (extramedullary hematopoiesis), which become enlarged, causing severe discomfort, inability to eat, and weakness. Symptomatic myelofibrosis affects approximately 18,000 people per year in the US, with a median age of 61-66.². The only potentially curative treatment is allogeneic bone marrow transplant, which results in reversal of fibrosis and all symptoms, but is a realistic option for only a small number of patients. Other currently available therapies address the symptoms, but have minimal if any impact on the underlying fibrosis.

About PRM-151

PRM-151, Promedior's lead product candidate, is a recombinant form of an endogenous human protein, Pentraxin-2 (PTX-2), that is specifically active at the site of tissue damage. PRM-151 is an agonist that acts as a macrophage differentiation factor to prevent and potentially reverse fibrosis. PRM-151 has shown broad anti-fibrotic activity in multiple preclinical models of fibrotic disease, including pulmonary fibrosis, acute and chronic nephropathy, liver fibrosis, and age-related macular degeneration.

Phase 1a and 1b clinical studies in healthy subjects and IPF patients have demonstrated that PRM-151 was safe and well tolerated. Additionally, a Phase 1b study in patients with IPF showed encouraging results in exploratory efficacy endpoints, which were presented in an oral session at the 2013 Annual Meeting of the American Thoracic Society³.

About Promedior

Promedior is a clinical stage biotechnology company pioneering the development of targeted therapeutics to treat diseases involving fibrosis. Fibrosis is a harmful process that occurs in many diseases, when normal healthy tissue is replaced with excessive scar tissue, compromising function and ultimately leading to organ failure. Promedior's proprietary platform is based upon Pentraxin-2, an endogenous human protein that is specifically active at the site of tissue damage and works as an agonist, potentially preventing and reversing fibrosis.

Promedior has successfully advanced its lead therapeutic candidate in human clinical trials, and is initially focused on rare fibrotic diseases, including idiopathic pulmonary fibrosis (IPF) and myelofibrosis. Promedior is backed by leading global healthcare venture investors, has a significant intellectual property estate relating to the discoveries and applications of Pentraxin-2 therapeutics and is led by an experienced management team. For additional information about Promedior, please visit www.promedior.com.

 
1. Tefferi, A., et al, "Revised Response Criteria for Myelofibrosis: International Working Group- Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report," Blood 122(8): 1395-8; 2013.
 
2. Mehta, J., Wang, H., Iqbal, S. U., Mesa, R., "Epidemiology of myeloproliferative neoplasms in the United States", Leukemia & Lymphoma, Early Online: 1-6, 2013.
 
3.

Van Den Blink, B. et al., "A Phase I Study Of PRM-151 In Patients With Idiopathic Pulmonary Fibrosis", American Thoracic Society 2013 Annual Meeting, May 2013. Read More: http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A5707

 

Media:
The Yates Network
Kathryn Morris, 845-635-9828
[email protected]


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
03:39a CENERGY : Consolidated Annual Report 2016
03:36aDJLAURENCE FINK : BlackRock's Fink Voices Concerns With Trump Tax Plan -- 2nd Update
03:35a AIR METHODS : Vote on air ambulance at special county meeting
03:34a CPI CARD : Altamaha Bank & Trust Leverages CPI Card Group’s [email protected]® Instant Issuance Program To Support Innovative Local Marketing Initiative
03:34a CPI CARD : Announces CEO Retirement Plan and Succession Process
03:34a GRUPO TELEVISA : Files Form 20-F
03:29a CENERGY : Publication of the Annual Report 2016
03:29a USAC UNITED STATES AUTO CLUB : Bobby santos wins pole for saturday's phoenix copper cup
03:29a GRUPO TELEVISA : TV - Grupo Televisa Files Form 20
03:26a Horizons ETFs Completes Conversion of Advisor-Class Units to Common Class Units
Latest news
Advertisement
Hot News 
5.97%REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects for eczema drug
-3.42%INTEL : revenue misses estimates as data centre growth slows
5.37%AIR BERLIN : Restructuring costs drive Air Berlin to record loss
3.71%Google parent Alphabet's profit up 29 percent on strong ad sales
-3.79%SCHWEIZERISCHE NATIONALBANK : Swiss central bank shareholders lose battle over dividend hike
Most Read News
08:10p Time Inc and Meredith Corp end talks over merger deal
08:18p Apple, Tesla ask California to change proposed self-driving car test policy
06:08p U.S. appeals court blocks Anthem bid to merge with rival Cigna
08:22p BOEING : wins $541 million defence contract - Pentagon
08:22p GENERAL ELECTRIC WINS $670 MILLION AIRCRAFT ENGINE MAINTENANCE CONTRACT : Pentagon
Most recommended articles
04/27 JPMorgan Chase & Co leaves blockchain consortium R3
04/21 TWENTY FIRST CENTURY FOX : Government extends period for regulators to report on Sky-Fox merger
09:36pDJLAURENCE FINK : BlackRock's Fink Voices Concerns With Trump Tax Plan -- 2nd Update
08:22p BOEING : wins $541 million defence contract - Pentagon
08:22p LOCKHEED MARTIN : wins $1.38 billion F-35 jet contract - Pentagon